NMRA
NASDAQNeumora Therapeutics Inc.
News25/Ratings12
News · 26 weeks43+600%
2025-10-262026-04-19
Mix1890d
- SEC Filings9(50%)
- Insider4(22%)
- Other2(11%)
- Earnings2(11%)
- Analyst1(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by Neumora Therapeutics Inc.DEFA14A - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECSEC Form DEF 14A filed by Neumora Therapeutics Inc.DEF 14A - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare ConferenceWATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m. ET. A live webcast of the fireside chat will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived fo
- SECSEC Form S-8 filed by Neumora Therapeutics Inc.S-8 - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECSEC Form 10-K filed by Neumora Therapeutics Inc.10-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateNew data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promising clinical results from ongoing Phase 1 study Strong financial position with $182.5 million in cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 Company to host conference call today at 8:00 a.m. ET WATERTOWN, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinica
- PRNeumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of th
- INSIDEROfficer Aurora Daljit Singh sold $21,917 worth of shares (6,165 units at $3.56), decreasing direct ownership by 7% to 82,770 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERPresident Pinto Joshua sold $21,093 worth of shares (5,967 units at $3.54), decreasing direct ownership by 9% to 57,783 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDEROfficer Berns Paul L sold $34,459 worth of shares (9,819 units at $3.51), decreasing direct ownership by 0.13% to 7,395,185 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDEROfficer Milligan Michael Lee sold $5,119 worth of shares (1,436 units at $3.56), decreasing direct ownership by 6% to 21,034 units (SEC Form 4)4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- SECSEC Form 144 filed by Neumora Therapeutics Inc.144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
- ANALYSTNeumora Therapeutics upgraded by William BlairWilliam Blair upgraded Neumora Therapeutics from Mkt Perform to Outperform
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- PRNeumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and
- ANALYSTLeerink Partners initiated coverage on Neumora Therapeutics with a new price targetLeerink Partners initiated coverage of Neumora Therapeutics with a rating of Outperform and set a new price target of $8.00
- SECNeumora Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
- INSIDERSEC Form 4 filed by Officer Milligan Michael Lee4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Officer Aurora Daljit Singh4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Officer Duncan Jason4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by President Pinto Joshua4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
- INSIDERSEC Form 4 filed by Officer Berns Paul L4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)